SARS
8
0
0
6
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 8 trials
100.0%
+13.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 6 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 6 completed trials
Clinical Trials (8)
Modulation of Hyperinflammation in COVID-19
Zofin (Organicell Flow) for Patients With COVID-19
Characterization of Cardiovascular Diseases and Risk Factors in Patients With Suspected SARS-CoV2/Covid-19 Infection
Clinical Trial of Sarilumab in Adults With COVID-19
Tocilizumab vs CRRT in Management of Cytokine Release Syndrome (CRS) in COVID-19
Collection of Convalescent SARS Plasma by Apheresis
Phase I Dose Escalation SARS-CoV Recombinant S Protein, With and Without Adjuvant, Vaccine Study
Dynamic Profiles of Cytokine/Chemokine in Severe Acute Respiratory Syndrome